Castuner

Taylor & Francis

Taylor & Francis Group

Podcast by Taylor & Francis Group

Podcast website

Listen in your app

Episodes

333 episodes

  1. POLARIS: encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis 5:10
  2. Decoding clinical trial jargon: helping people understand the efficacy end points used in cancer trials 13:49
  3. The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer 16:39
  4. Decoding clinical trial jargon: helping people understand how safety and quality of life are assessed in cancer trials 20:24
  5. Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer 13:49
  6. The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer 14:30
  7. Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study 16:24
  8. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment 14:39
  9. Podcast 3. Lessons Learned: Managing Financial Costs and where you can go for more Information 26:42
  10. Podcast 2. The Journey: Staying on top of your Cancer 29:15
  11. The Beginning: Diagnosis and Selecting Your Doctor 33:23
  12. Podcast article: Biomarker testing in colorectal cancer - Future Oncology 8:55
  13. HER2-positive breast cancer: Insights into treatment selection and sequencing 7:54
  14. Navigating oligometastatic breast cancer: the role of stereotactic radiotherapy 15:57
  15. First-line management of unresectable hepatocellular carcinoma: clinical perspectives from the CheckMate 9DW study 14:24
  16. Enzalutamide in biochemically recurrent prostate cancer: clinical implications from EMBARK for real-world practice 47:31
  17. Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice 26:45
  18. Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study 26:03
  19. Practical advice on implementing DESTINY-Breast09 trial data into clinical practice 7:12
  20. 2026 BRSA Finalist Giorgi Kobidze 0:44
  21. 2026 BRSA Finalist Richa Pandey 0:29
  22. Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study 20:14
  23. 2026 BRSA Finalist Dakshat Trivedi 0:30
  24. 2026 BRSA Finalist Ethan Sanford 0:28
  25. Harmonizing scientific innovation, patient care and regulation in advanced therapies: a podcast with Patrice Faloye 22:10
  26. Breaking barriers in neurodegenerative disorders with gene therapy: a podcast with Deborah Ojutalayo 8:29
  27. Innovating and developing tissue engineering beyond replacement: a podcast with Guillermo Ameer 17:40
  28. Research and progress in sickle cell disease and thalassemia: a podcast with Baba Inusa 19:54
  29. Tackling the rise in early onset cancer: From research to health equity 12:02
  30. Trends, tools and transformation: the evolution of flow cytometry in bioanalysis 23:37
  31. 115 analytes, one panel: a conversation on innovation in biomarker discovery 13:20
  32. Exploring biomarker testing in clinical research 17:08
  33. First void urine: revolutionizing potential non-invasive biomarker collection 14:07
  34. STEM Tea | Investing in our students 36:27
  35. LC–MS/MS for quantitation of protein biomarkers 20:10
  36. STEM Tea | Being visible as an act of service 56:45
  37. STEM Tea | Founding Black in Neuro 40:57
  38. STEM Tea | Disrupting racism and cisheteropatriarchy through research, pedagogy and mentorship in STEM education 40:36
  39. STEM Tea | Strengthening HBCUs 1:00:49
  40. STEM Tea | Working together for better science and better opportunities 45:23
  41. STEM Tea | Impact and sustainability in mentorship 49:50
  42. STEM Tea | Supporting underserved communities through STEM mentorship 57:32
  43. From sensitivity to selectivity: transforming mass spectrometry imaging with targeted solutions 21:55
  44. Unveiling bioanalytical datasets for the successful development of ADCs 19:03
  45. Bridging science and safety: exploring toxicology studies and regulatory requirements 10:50
  46. Cell therapies for autoimmune diseases: a podcast with Lindsay Davies 13:17
  47. The use of GenAI in bioanalysis: an interview with Priyata Kalra 28:30
  48. The need for HRMS for quantitation of ADCs vs. QQQ: an interview with Megan Cooley 21:35
  49. How can medical device regulation catch up with innovation? 12:36
  50. The new frontier: assessing efficacy and safety of CGTs using biomarkers 24:21